From the Podium to Your Practice: Dr. Christopher Bunick Discusses New Real-world Safety Data on Upadacitinib (Rinvoq, AbbVie) in AD
New research provides evidence about the safety of upadacitinib when it comes to long-term incidence rates of MACE, VTE, and malignancy (excluding NMSC).